KPTI— Karyopharm Therapeutics Inc.

MaterialsBiotechnology$48M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenue from contract with customer, license and other revenue	$146.1M+0.6%	$145.2M-0.5%	$146.0M-7.0%	$157.1M
Research and development	$125.6M-12.3%	$143.2M+3.2%	$138.8M-6.7%	$148.7M
Selling, general and administrative	$105.2M-8.9%	$115.4M-12.5%	$131.9M-9.3%	$145.4M
Total operating expenses	$236.8M-10.5%	$264.7M-4.0%	$275.6M-7.9%	$299.3M
Loss from operations	-$90.7M+24.1%	-$119.4M+7.8%	-$129.5M+8.9%	-$142.2M
Interest income	$2.8M-62.5%	$7.4M-32.4%	$10.9M+363.9%	$2.4M
Interest expense	-$45.8M-22.5%	-$37.4M-57.1%	-$23.8M+4.7%	-$25.0M
(Loss) gain on extinguishment of debt	-$62.4M-239.5%	$44.7M	$0	$0
Other income (expense), net	$152K-99.5%	$28.4M+8077.0%	-$356K-328.9%	-$83K
Total other (expense) income, net	-$105.3M-344.4%	$43.1M+425.5%	-$13.2M+41.7%	-$22.7M
Loss before income taxes	-$196.0M-156.7%	-$76.4M+46.5%	-$142.8M+13.4%	-$164.9M
Income tax provision	-$43K+24.6%	-$57K+82.4%	-$323K+12.5%	-$369K
Net loss	-$196.0M-156.5%	-$76.4M+46.6%	-$143.1M+13.4%	-$165.3M
Basic net loss per share	-$17930.00-90.5%	-$9410.00+49.9%	-$18790.00-830.2%	-$2020.00
Diluted net loss per share (Note 2)	-$17930.00-28.1%	-$14000.00+25.5%	-$18790.00-830.2%	-$2020.00
Weighted-average number of common shares outstanding used to compute basic net loss per share	$10935000.00+34.6%	$8125000.00+6.7%	$7616000.00-90.7%	$81871000.00
Weighted-average number of common shares outstanding used to compute diluted net loss per share	$10935000.00+29.3%	$8455000.00+11.0%	$7616000.00-90.7%	$81871000.00
Product [Member]
Cost of sales	$5.9M-1.0%	$6.0M+21.5%	$4.9M-5.2%	$5.2M
License and Other [Member]

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.